-
1
المؤلفون: Michal Stark, Elisa Giovannetti, Gerrit Jansen, Larry H. Matherly, Maria Gemelli, Godefridus J. Peters, Erik Thunnissen, Ittai B. Muller, Zhanjun Hou, P. A. Zucali, E. A. Struys, Niccola Funel, M. Perrino, Yehuda G. Assaraf
المساهمون: Medical oncology laboratory, CCA - Cancer biology and immunology, Pathology, Clinical chemistry, AGEM - Inborn errors of metabolism, AGEM - Endocrinology, metabolism and nutrition, Rheumatology, AGEM - Digestive immunity
المصدر: Annals of Oncology, 28(11), 2725-2732. Oxford University Press
Giovannetti, E, Zucali, P A, Assaraf, Y G, Funel, N, Gemelli, M, Stark, M, Thunnissen, E, Hou, Z, Muller, I B, Struys, E A, Perrino, M, Jansen, G, Matherly, L H & Peters, G J 2017, ' Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma : Clinical evidence and new pharmacological tools ', Annals of Oncology, vol. 28, no. 11, pp. 2725-2732 . https://doi.org/10.1093/annonc/mdx499Testمصطلحات موضوعية: Male, Mesothelioma, 0301 basic medicine, Oncology, Thymidylate synthase, Immunoenzyme Techniques, Reduced Folate Carrier Protein, chemistry.chemical_compound, 0302 clinical medicine, Tumor Cells, Cultured, Aged, 80 and over, biology, Hematology, Methylation, Middle Aged, Prognosis, Survival Rate, Pemetrexed, 030220 oncology & carcinogenesis, Antifolate, Immunohistochemistry, Female, Proton-Coupled Folate Transporter, medicine.drug, Adult, medicine.medical_specialty, Pleural Neoplasms, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, medicine, Humans, Gene silencing, Survival rate, Aged, Cell Proliferation, business.industry, Original Articles, Thymidylate Synthase, medicine.disease, 030104 developmental biology, chemistry, Drug Resistance, Neoplasm, biology.protein, Folic Acid Antagonists, business, Follow-Up Studies
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ccf6187f967e64fb83a9f2dcd466830Test
https://doi.org/10.1093/annonc/mdx499Test -
2
المؤلفون: Henk L. Dekker, Elisa Giovannetti, Marcello Tiseo, Patrick Pauwels, Filip Lardon, Christian Rolfo, Kaylee Keller, Rob Ruijtenbeek, Alessandro Leonetti, Niccola Funel, Godefridus J. Peters, Nele Van Der Steen
المساهمون: Medical oncology laboratory, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer biology and immunology
المصدر: Biochemical pharmacology
van der Steen, N, Leonetti, A, Keller, K, Dekker, H, Funel, N, Lardon, F, Ruijtenbeek, R, Tiseo, M, Rolfo, C, Pauwels, P, Peters, G J & Giovannetti, E 2019, ' Decrease in phospho-PRAS40 plays a role in the synergy between erlotinib and crizotinib in an EGFR and cMET wild-type squamous non-small cell lung cancer cell line ', Biochemical Pharmacology, vol. 166, pp. 128-138 . https://doi.org/10.1016/j.bcp.2019.05.014Test
Biochemical Pharmacology, 166, 128-138. Elsevier Inc.مصطلحات موضوعية: 0301 basic medicine, MAPK/ERK pathway, Male, Lung Neoplasms, Antineoplastic Agents, Biochemistry, 03 medical and health sciences, Erlotinib Hydrochloride, 0302 clinical medicine, Crizotinib, Carcinoma, Non-Small-Cell Lung, Cell Line, Tumor, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Epidermal growth factor receptor, Phosphorylation, Lung cancer, Protein kinase B, PI3K/AKT/mTOR pathway, Adaptor Proteins, Signal Transducing, Aged, Pharmacology, biology, Chemistry, Pharmacology. Therapy, Drug Synergism, Cell cycle, Middle Aged, Proto-Oncogene Proteins c-met, medicine.disease, ErbB Receptors, 030104 developmental biology, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Female, Erlotinib, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::198c1da7976161631dcc7ca088486798Test
https://hdl.handle.net/10067/1611930151162165141Test -
3
المؤلفون: C. J. van Groeningen, Elisa Giovannetti, G.J. Peters, R. Ruijter, Henk M.W. Verheul, Giuseppe Giaccone, A. A. van Zweeden, Richard J. Honeywell, Carolien H. Smorenburg, Hans J. van der Vliet
المساهمون: Medical oncology, Medical oncology laboratory, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and quality of life
المصدر: van Zweeden, A A, van Groeningen, C J, Honeywell, R J, Giovannetti, E, Ruijter, R, Smorenburg, C H, Giaccone, G, Verheul, H M W, Peters, G J & van der Vliet, H J 2018, ' Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer ', Cancer Chemotherapy and Pharmacology, vol. 82, no. 1, pp. 39-48 . https://doi.org/10.1007/s00280-018-3588-6Test
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 82(1), 39-48. Springer Verlagمصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Folic acid, Esophageal Neoplasms, Esophagogastric cancer, Cmax, Phases of clinical research, Adenocarcinoma, Toxicology, Gastroenterology, Deoxycytidine, 03 medical and health sciences, 0302 clinical medicine, Stomach Neoplasms, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Humans, Pharmacology (medical), Vitamin B12, Aged, Pharmacology, Cisplatin, Aged, 80 and over, business.industry, Drug Synergism, Middle Aged, medicine.disease, Gemcitabine, Vitamin B 12, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Toxicity, Dietary Supplements, Original Article, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2502b3d61670f51491c3457468559503Test
https://research.vumc.nl/en/publications/2bf1b93c-372d-48e0-ac96-fc8c6c2699d3Test -
4
المؤلفون: Godefridus J. Peters, Isabella Vittimberga, Editta Baldini, Myriam Chartoire, Luca Boni, Marcello Tiseo, Matteo Brighenti, Fausto Barbieri, Andrea Camerini, Elisa Giovannetti, Francesca Mazzoni, Carmelo Tibaldi, Annalisa Gilli, Richard J. Honeywell
المساهمون: CCA - Imaging and biomarkers, Medical oncology laboratory, AGEM - Re-generation and cancer of the digestive system
المصدر: British journal of cancer, 119(11), 1326-1331. Nature Publishing Group
British Journal of Cancer, 119(11), 1326-1331. Nature Publishing Group
Tibaldi, C, Camerini, A, Tiseo, M, Mazzoni, F, Barbieri, F, Vittimberga, I, Brighenti, M, Boni, L, Baldini, E, Gilli, A, Honeywell, R, Chartoire, M, Peters, G J, Giovannetti, E & Italian Oncological Group of Clinical Research (GOIRC) 2018, ' Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer : a prospective validation study ', British Journal of Cancer, vol. 119, no. 11, pp. 1326-1331 . https://doi.org/10.1038/s41416-018-0307-3Test
British Journal of Cancerمصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Predictive markers, Deoxycytidine, Article, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Medical research, Internal medicine, Carcinoma, Non-Small-Cell Lung, Cytidine Deaminase, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Biomarkers, Tumor, Humans, Prospective Studies, Prospective cohort study, Lung cancer, Survival rate, Aged, Retrospective Studies, Aged, 80 and over, business.industry, Retrospective cohort study, Cytidine deaminase, Middle Aged, medicine.disease, Prognosis, Gemcitabine, 030104 developmental biology, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, Cisplatin, business, Non-small-cell lung cancer, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::70a41cf0b0a4002de132af4198423642Test
https://pure.amc.nl/en/publications/cytidine-deaminase-enzymatic-activity-is-a-prognostic-biomarker-in-gemcitabineplatinumtreated-advanced-nonsmallcell-lung-cancer-a-prospective-validation-studyTest(297ba0b2-d07b-4b73-bc30-89fce3b095d5).html -
5
المؤلفون: Carlotta Granchi, Elisa Giovannetti, Amir Avan, Babette Aicher, Daniela Massihnia, Mina Maftouh, Leticia G. Leon, Rajiv S. Raktoe, Anne van Krieken, Niccola Funel, Filippo Minutolo, Antonio Russo, Ugo Boggi, Godefridus J. Peters
المساهمون: Massihnia, D., Avan, A., Funel, N., Maftouh, M., Van Krieken, A., Granchi, C., Raktoe, R., Boggi, U., Aicher, B., Minutolo, F., Russo, A., Leon, L., Peters, G., Giovannetti, E., CCA - Cancer biology and immunology, AGEM - Digestive immunity, Medical oncology laboratory, AGEM - Re-generation and cancer of the digestive system
المصدر: Massihnia, D, Avan, A, Funel, N, Maftouh, M, Van Krieken, A, Granchi, C, Raktoe, R, Boggi, U, Aicher, B, Minutolo, F, Russo, A, Leon, L G, Peters, G J & Giovannetti, E 2017, ' Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer ', Journal of Hematology and Oncology, vol. 10, no. 1, 9 . https://doi.org/10.1186/s13045-016-0371-1Test
Journal of Hematology & Oncology
Journal of Hematology and Oncology, 10(1):9. BioMed Central
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-17 (2017)مصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, Biopsy, AKT1, Apoptosis, Akt, Gemcitabine, Pancreatic ductal adenocarcinoma, Synergism, Hematology, Molecular Biology, Deoxycytidine, 0302 clinical medicine, Cell Movement, Tumor Cells, Cultured, Glucose Transporter Type 1, medicine.diagnostic_test, Chemistry, Cell Cycle, Pancreatic Neoplasm, Drug Synergism, lcsh:Diseases of the blood and blood-forming organs, Cell cycle, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, Aged, Carcinoma, Pancreatic Ductal, Female, Humans, Pancreatic Neoplasms, Phosphoproteins, Proto-Oncogene Proteins c-akt, RNA, Messenger, Spheroids, Cellular, 030220 oncology & carcinogenesis, Phosphoprotein, medicine.drug, Human, medicine.medical_specialty, Prognosi, lcsh:RC254-282, Flow cytometry, 03 medical and health sciences, Internal medicine, Pancreatic cancer, medicine, Protein kinase B, PI3K/AKT/mTOR pathway, lcsh:RC633-647.5, Research, Apoptosi, medicine.disease, 030104 developmental biology, Cancer cell, Cancer research
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f0527d043c396c119ac955e1ab571ea8Test
https://research.vumc.nl/en/publications/e3915272-5f2e-4b5f-a149-4af093da963cTest -
6
المؤلفون: S. Caponi, Elisa Paolicchi, Daniela Campani, Pinuccia Faviana, Elisa Giovannetti, Godefridus J. Peters, Niccola Funel, Ugo Boggi, Amir Avan, Paola Pacetti, Enrico Vasile, Michele Reni, Mina Maftouh, Andrea Mambrini, Michele Milella, Vanja Vaccaro, Maurizio Cantore
المساهمون: Medical oncology laboratory, CCA - Innovative therapy
المصدر: Maftouh, M, Avan, A, Funel, N, Paolicchi, E, Vasile, E, Pacetti, P, Vaccaro, V, Faviana, P, Campani, D, Caponi, S, Mambrini, A, Boggi, U, Cantore, M, Milella, M, Peters, G J, Reni, M & Giovannetti, E 2014, ' A polymorphism in the promoter is associated with EZH2 expression but not with outcome in advanced pancreatic cancer patients ', Pharmacogenomics, vol. 15, no. 5, pp. 609-618 . https://doi.org/10.2217/pgs.13.225Test
Università di Pisa-IRIS
Pharmacogenomics, 15(5), 609-618. Future Medicine Ltd.مصطلحات موضوعية: Male, Antimetabolites, Antineoplastic, Prognostic factor, Pancreatic ductal adenocarcinoma, Antimetabolites, Locally advanced, macromolecular substances, Deoxycytidine, Promoter Regions, Cohort Studies, Genetic, Pancreatic cancer, Genetics, medicine, Humans, SNP, Enhancer of Zeste Homolog 2 Protein, Polymorphism, Promoter Regions, Genetic, Aged, Pharmacology, Polymorphism, Genetic, business.industry, EZH2, Polycomb Repressive Complex 2, DNA, Middle Aged, medicine.disease, Antineoplastic, Survival Analysis, Gemcitabine, Pancreatic Neoplasms, MicroRNAs, Treatment Outcome, Cohort, Disease Progression, Cancer research, Molecular Medicine, Female, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bc8f783cd084710d92d4ab8ad3e724eTest
https://doi.org/10.2217/pgs.13.225Test -
7
المؤلفون: Richard J. Honeywell, Joseph Ciccolini, Nienke Losekoot, Cindy Serdjebi, M. Maulandi, M.C. Etienne-Grimaldi, Elisa Giovannetti, G.J. Peters, G. Milano
المساهمون: Medical oncology laboratory, CCA - Innovative therapy
المصدر: Nucleosides, Nucleotides and Nucleic Acids, 33(4-6), 403-412. Taylor and Francis Ltd.
Peters, G J, Honeywell, R J, Maulandi, M, Giovannetti, E, Losekoot, N, Etienne-Grimaldi, M C, Milano, G, Serdjebi, C & Ciccolini, J 2014, ' Selection of the Best Blood Compartment to Measure Cytidine Deaminase Activity to Stratify for Optimal Gemcitabine Or Cytarabine Treatment ', Nucleosides, Nucleotides and Nucleic Acids, vol. 33, no. 4-6, pp. 403-412 . https://doi.org/10.1080/15257770.2014.894196Testمصطلحات موضوعية: Adult, Male, Cytidine deaminase activity, Cost-Benefit Analysis, Pharmacology, Biochemistry, Deoxycytidine, chemistry.chemical_compound, Young Adult, Cytidine Deaminase, Genetics, medicine, Humans, Dosing, Whole blood, Enzyme Assays, Chemistry, Cytarabine, Reproducibility of Results, Cytidine, General Medicine, Cytidine deaminase, Middle Aged, Gemcitabine, Toxicity, Molecular Medicine, Female, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc886224b3c27ee84817938ec30aa529Test
https://doi.org/10.1080/15257770.2014.894196Test -
8
المساهمون: Surgery, Medical oncology laboratory, CCA - Target Discovery & Preclinial Therapy Development
المصدر: Meijer, L L, Puik, J R, Peters, G J, Kazemier, G & Giovannetti, E 2016, ' hENT-1 Expression and Localization Predict Outcome After Adjuvant Gemcitabine in Resected Cholangiocarcinoma Patients ', The Oncologist, vol. 21, no. 12, pp. e4 . https://doi.org/10.1634/theoncologist.2016-0262Test
The Oncologist
The Oncologist, 21(12). AlphaMed Pressمصطلحات موضوعية: 0301 basic medicine, Oncology, Male, Cancer Research, medicine.medical_specialty, Antimetabolites, Antineoplastic, medicine.medical_treatment, Treatment outcome, Equilibrative nucleoside transporter 1, Deoxycytidine, Disease-Free Survival, Cholangiocarcinoma, Equilibrative Nucleoside Transporter 1, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, In patient, Letters to the Editor, Aged, Chemotherapy, biology, business.industry, Middle Aged, Gemcitabine, 030104 developmental biology, Bile Duct Neoplasms, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, biology.protein, Biomarker (medicine), Female, business, Adjuvant, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2356f1bce196ea80a75555ea4263dae6Test
https://doi.org/10.1634/theoncologist.2016-0262Test -
9
المؤلفون: Jacobus A. Burgers, Godefridus J. Peters, Egbert F. Smit, Elisa Giovannetti, Francesco Di Costanzo, Andrea Ardizzoni, Carmelo Tibaldi, Andrea Camerini, Fausto Barbieri, Marcello Tiseo, Andrew D. Vincent
المساهمون: Medical oncology laboratory, Pulmonary medicine, CCA - Innovative therapy, Tiseo, Marcello, Giovannetti, Elisa, Tibaldi, Carmelo, Camerini, Andrea, Di Costanzo, Francesco, Barbieri, Fausto, Burgers, Jacobus A., Vincent, Andrew, Peters, Godefridus J., Smit, Egbert F., Ardizzoni, Andrea
المصدر: Lung Cancer, 78(1), 92-99. Elsevier Ireland Ltd
Tiseo, M, Giovannetti, E, Tibaldi, C, Camerini, A, Di Costanzo, F, Barbieri, F, Burgers, J A, Vincent, A D, Peters, G J, Smit, E F & Ardizzoni, A 2012, ' Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin ', Lung Cancer, vol. 78, no. 1, pp. 92-99 . https://doi.org/10.1016/j.lungcan.2012.07.009Testمصطلحات موضوعية: Male, Oncology, Cancer Research, Lung Neoplasms, non-small cell lung cancer (NSCLC), Pharmacology, Thymidylate synthase, Carboplatin, Antineoplastic Agent, Reduced Folate Carrier Protein, chemistry.chemical_compound, Gene Frequency, Glutamates, Retrospective Studie, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Allele, Aged, 80 and over, biology, Pharmacogenetic, Hazard ratio, Middle Aged, Treatment Outcome, Pemetrexed, Female, Glutamate, Human, medicine.drug, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Guanine, Genotype, Non-small cell lung cancer (NSCLC), Antineoplastic Agents, Polymorphism, Single Nucleotide, Internal medicine, medicine, Humans, Alleles, Methylenetetrahydrofolate Reductase (NADPH2), Aged, Neoplasm Staging, Retrospective Studies, Xeroderma Pigmentosum Group D Protein, Antineoplastic Combined Chemotherapy Protocol, business.industry, Proportional hazards model, Thymidylate Synthase, gamma-Glutamyl Hydrolase, MTHFR-C667T polymorphism, medicine.disease, Lung Neoplasm, chemistry, Methylenetetrahydrofolate reductase, biology.protein, business, Pharmacogenetics
وصف الملف: ELETTRONICO
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9e75b870f6ebcd4b15db069e24f07cf1Test
https://doi.org/10.1016/j.lungcan.2012.07.009Test -
10
المساهمون: Medical oncology laboratory, CCA - Innovative therapy
المصدر: Journal of Cancer Research and Clinical Oncology, 141(7), 1189-1194. Springer Verlag
Vasile, E, Tibaldi, C, Leon, G L, D'Incecco, A & Giovannetti, E 2015, ' Cytochrome P450 1B1 (CYP1B1) polymorphisms are associated with clinical outcome of docetaxel in non-small cell lung cancer (NSCLC) patients ', Journal of Cancer Research and Clinical Oncology, vol. 141, no. 7, pp. 1189-1194 . https://doi.org/10.1007/s00432-014-1880-3Testمصطلحات موضوعية: Male, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, CYP1B1, medicine.medical_treatment, non-small cell lung cancer (NSCLC), Antineoplastic Agents, Single-nucleotide polymorphism, Docetaxel, Polymorphism, Single Nucleotide, Biomarkers, Pharmacological, Polymorphism (computer science), Carcinoma, Non-Small-Cell Lung, Internal medicine, Tumor Cells, Cultured, medicine, Carcinoma, Humans, neoplasms, Genetic Association Studies, Aged, Retrospective Studies, Aged, 80 and over, Chemotherapy, Hematology, business.industry, General Medicine, Middle Aged, Prognosis, medicine.disease, body regions, Treatment Outcome, Chemotherapy, Adjuvant, Cytochrome P-450 CYP1B1, Female, Taxoids, business, medicine.drug
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c5595da0c67b8409b2e8a1b7b1b23d1Test
https://research.vumc.nl/en/publications/96018efa-575a-443a-b58a-d1486c35ebb8Test
